In patients with AHA who do not respond to immunosuppressive regimens, the administration of IVIG 1.0 g/kg/d for 2 days or 0.4 g/kg/d for 5 days is recommended IVIG has poor efficacy in the AHA, and therefore its use for the purpose of blocking autoantibodies to FVIII is not recommended. The gene discussed is F8; the disease is autoimmune hemolytic anemia.